Quality over quantity: A qualitative, targeted bottom-up proteomics approach to genotyping apolipoprotein L1

Clinical Biochemistry - Tập 82 - Trang 58-65 - 2020
Meghan Norris Bradley1, Christopher M. Shuford1, Patricia L. Holland1, Michael Levandoski1, Russell P. Grant1
1Laboratory Corporation of America Holdings, Center for Esoteric Testing, Burlington, NC, United States

Tài liệu tham khảo

Chen, 2011, Simultaneous phenotyping and quantification of -1-antitrypsin by liquid chromatography-tandem mass spectrometry, Clin. Chem., 57, 1161, 10.1373/clinchem.2011.163006 Lim, 2002, Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis, Anal. Chem., 74, 741, 10.1021/ac010780+ Wild, 2001, Rapid identification of hemoglobin variants by electrospray ionization mass spectrometry, Blood Cells, Mol. Dis., 27, 691, 10.1006/bcmd.2001.0430 Nishimura, 2014, Human apolipoprotein E resequencing by proteomic analysis and its application to serotyping, PloS one, 9, 7, 10.1371/journal.pone.0085356 He, 2019, Diagnosis of hemoglobinopathy and β-thalassemia by 21 tesla fourier transform ion cyclotron resonance mass spectrometry and tandem mass spectrometry of hemoglobin from blood, Clin. Chem., 65, 986, 10.1373/clinchem.2018.295766 Maus, 2019, Center of mass calculation in combination with MS/MS allows robust identification of single amino acid polymorphisms in clinical measurements of insulin-like growth factor-1, J. Proteome Res., 19, 186, 10.1021/acs.jproteome.9b00494 Limou, 2014, APOL1 kidney risk alleles: population genetics and disease associations, Adv. Chronic Kidney Dis., 21, 426, 10.1053/j.ackd.2014.06.005 Bruggeman, 2014, Plasma apolipoprotein L1 levels do not correlate with CKD, J. Am. Soc. Nephrol., 25, 634, 10.1681/ASN.2013070700 Genovese, 2010, Association of trypanolytic ApoL1 African Americans, 67 Kopp, 2011, APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy, J. Am. Soc. Nephrol., 22, 2129, 10.1681/ASN.2011040388 Friedman, 2011, Population-based risk assessment of APOL1 on renal disease, J. Am. Soc. Nephrol., 22, 2098, 10.1681/ASN.2011050519 Freedman, 2014, End-stage renal disease in African Americans with lupus nephritis is associated With APOL1, Arthritis Rheumatol., 66, 390, 10.1002/art.38220 Reeves-Daniel, 2011, The APOL1 gene and allograft survival after kidney transplantation, Am. J. Transplant., 11, 1025, 10.1111/j.1600-6143.2011.03513.x Freedman, 2015, Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure, Am. J. Transplant., 15, 1615, 10.1111/ajt.13223 Freedman, 2016, APOL1 genotype and kidney transplantation outcomes from deceased African American donors, Transplantation, 100, 194, 10.1097/TP.0000000000000969 Organ Procurement and Transplantation Network, A Guide to Calculating and Interpreting the Kidney Donor Profle Index (KDPI), (2019) 1–11. https://optn.transplant.hrsa.gov/media/1512/guide_to_calculating_interpreting_kdpi.pdf. Akkina, 2012, Development of organ-specific donor risk indices, Liver Transplant., 18, 395, 10.1002/lt.23398 Kopp, 2020, Genetic testing for APOL1 genetic variants in clinical practice finally starting to arrive, Clin. J. Am. Soc. Nephrol., 15, 126, 10.2215/CJN.01810219 Zhou, 2013, Rapid detection and quantification of apolipoprotein L1 genetic variants and total levels in plasma by ultra-performance liquid chromatography/tandem mass spectrometry, Rapid Commun. Mass Spectrom., 27, 2639, 10.1002/rcm.6734 Zhang, 2016, Analytical validation of a personalized medicine APOL1 genotyping assay for nondiabetic chronic kidney disease risk assessment, J. Mol. Diagnostics, 18, 260, 10.1016/j.jmoldx.2015.11.003 Madhavan, 2011, APOL1 localization in normal kidney and nondiabetic kidney disease, J. Am. Soc. Nephrol., 22, 2119, 10.1681/ASN.2011010069 MacLean, 2010, Skyline: an open source document editor for creating and analyzing targeted proteomics experiments, Bioinformatics, 26, 966, 10.1093/bioinformatics/btq054 MacLean, 2010, Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry, Anal. Chem., 82, 10116, 10.1021/ac102179j Kozlitina, 2016, Plasma levels of risk-variant APOL1 do not associate with renal disease in a population-based cohort, J. Am. Soc. Nephrol., 27, 3204, 10.1681/ASN.2015101121